Hikma Pharmaceuticals PLC
Company Profile
Business description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Contact
1 New Burlington Place
LondonW1S 2HR
GBRT: +44 2073992760
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,150
Stocks News & Analysis
stocks
After earnings is Apple stock a buy, sell or fairly valued?
stocks
Ask the analyst: Is the market underestimating Bapcor?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,753.30 | 1.70 | 0.02% |
| CAC 40 | 8,028.90 | 22.68 | 0.28% |
| DAX 40 | 22,037.83 | 126.09 | 0.58% |
| Dow JONES (US) | 44,593.65 | 123.24 | 0.28% |
| FTSE 100 | 8,777.39 | 9.59 | 0.11% |
| HKSE | 21,294.86 | 227.12 | -1.06% |
| NASDAQ | 19,643.86 | 70.41 | -0.36% |
| Nikkei 225 | 38,801.17 | 14.15 | 0.04% |
| NZX 50 Index | 12,893.31 | 24.14 | -0.19% |
| S&P 500 | 6,068.50 | 2.06 | 0.03% |
| S&P/ASX 200 | 8,486.60 | 2.60 | 0.03% |
| SSE Composite Index | 3,318.06 | 4.11 | -0.12% |